

Table S1: STROBE checklist of items that should be included in reports of cross-sectional studies.

Table S1: STROBE checklist of items that should be included in reports of cross-sectional studies.			Page No
	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
Methods			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3-5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3-5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	-
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	-
		(e) Describe any sensitivity analyses	5
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5-6
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5-6

		(b) Indicate number of participants with missing data for each variable of interest	-
Outcome data	15*	Report numbers of outcome events or summary measures	5-6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-9
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9-11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	9-11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Table S2. Linear mixed models with random effect associated with macronutrients and antioxidants of the breast milk without adjust by gestational age.

Main effects	Proteins	<i>p</i>	ABTS	<i>p</i>	FRAP	<i>p</i>	GSH	<i>p</i>	Catalase activity	<i>p</i>
Male	2.72±1.31	0.047	0.12±0.06	0.035	46.65±71.02	0.517	1.71±0.94	0.078	-3.85±2.10	0.077
Day 14	-1.18±1.26	0.360	-0.10±0.05	0.043	-25.32±55.18	0.650	-2.15±0.86	0.019	-0.02±1.52	0.991
Day 28	-3.41±1.43	0.025	-0.20±0.04	<0.001	-63.44±57.41	0.279	-2.50±0.89	0.009	3.31±1.99	0.110
Male:Day 14	-2.34±2.14	0.284	-0.06±0.08	0.411	-0.98±87.77	0.991	-0.36±1.40	0.799	3.30±2.59	0.215
Male:Day 28	-0.30±2.53	0.910	-0.11±0.07	0.104	51.27±94.13	0.591	-1.51±1.45	0.307	0.44±3.51	0.901
AIC / BIC	327.6 / 362.4		-4.4 / 31.4		766.9 / 802.7		313.5 / 349.7		369.3 / 404.1	

Data show coefficients ± standard error and *p*-Value (*p*) associated. In the models, female, and day 7 were considered as a reference. All models were adjusted by maternal weight, body fat in the first week postpartum, and neonatal Z-scores of birth weight, length, and head circumference. ABTS: 2, 2'-Azino-Bis-3-Ethylbenzothiazoline-6-Sulfonic Acid; FRAP: Ferric Reducing Antioxidant Power; GSH: reduced glutathione; AIC: Akaike information criterion; BIC: Bayesian information criterion.

Table S3. Linear mixed models with random effect associated with macronutrients and antioxidants of the breast milk without interaction terms.

Main effects	Proteins	<i>p</i>	ABTS	<i>p</i>	FRAP	<i>p</i>	GSH	<i>p</i>	Catalase activity	<i>p</i>
Male	1.34±0.72	0.074	0.05±0.04	0.200	41.95±48.61	0.400	1.20±0.47	0.016	-1.98±1.30	0.140
Day 14	-1.99±0.97	0.051	-0.12±0.04	0.002	-26.00±41.85	0.539	-2.32±0.67	0.002	1.25±1.27	0.331
Day 28	-3.53±1.09	0.003	-0.24±0.03	<0.001	-45.73±44.58	0.314	-3.07±0.68	<0.001	3.61±1.61	0.034
AIC / BIC	336.6 / 369.8		-2.4 / 31.7		779.5 / 813.7		320.7 / 355.2		378.6 / 411.8	

Data show coefficients ± standard error and *p*-Value (*p*) associated. In the models, female, and day 7 were considered as a reference. All models were adjusted by maternal weight, body fat in the first week postpartum, gestational age, and neonatal Z-scores of birth weight, length, and head circumference. ABTS: 2, 2'-Azino-Bis-3-Ethylbenzothiazoline-6-Sulfonic Acid; FRAP: Ferric Reducing Antioxidant Power; GSH: reduced glutathione; AIC: Akaike information criterion; BIC: Bayesian information criterion.